Immunocytokines: A promising approach to cancer immunotherapy

Pharmacology and Therapeutics

Volumn 80, Issue 3, 1998, Pages 277-292

  Lode, Holger N ^a   Xiang, Rong ^a   Becker, Jürgen C ^b   Gillies, Stephen D ^c   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Lexigen Pharmaceuticals Corp   (United States)

Author keywords

Immunocytokines; Immunotherapy; Interleukin 2; Monoclonal antibodies; Natural killer cells; T cells

Indexed keywords

CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 2;

BONE MARROW METASTASIS; CANCER IMMUNOTHERAPY; CANCER MODEL; COLORECTAL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE;

EID: 0032403828     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00033-3     Document Type: Review

References (62)

1. Bajorin D.F., Chapman P.B., Wong G., Coit D.G., Kunicka J., Dimaggio J., Cordon-Cardo C., Urmacher C., Dantes L., Templeton M.A., Liu J., Oettgen H.F., Houghton A.N. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin-2 in patients with metastatic melanoma. Cancer Res. 50:1990;7490-7495.
2. Becker J.C., Pancook J.D., Gillies S.D., Furukawa K., Reisfeld R.A. T-cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin-2 therapy. J. Exp. Med. 183:1996;2361-2366. a.
3. Becker J.C., Varki N.M., Gillies S.D., Furukawa K., Reisfeld R.A. An antibody-interleukin-2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA. 93:1996;7826-7831. b.
4. Becker J.C., Varki N.M., Gillies S.D., Furukawa K., Reisfeld R.A. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98:1997;2801-2804.
5. Carson W.E., Lindemann M.J., Baiocchi R., Linett M., Tan J.C., Chou C.C., Narula S., Caligiuri M.A. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood. 85:1995;3577-3585.
6. Chen T.T., Tao M.H., Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153:1994;4775-4787.
7. Cheung N.K., Cheung I.Y., Canete A., Yeh S.J., Kushner B., Bonilla M.A., Heller G., Larson S.M. Antibody response to murine anti-GD2 monoclonal antibodies. correlation with patient survival Cancer Res. 54:1994;2228-2233.
8. Epstein A.L., Marder R.J., Winter J.N., Stathopoulos E., Chen F.M., Parker J.W., Taylor C.R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 47:1987;830-840.
9. Favrot M.C., Floret D., Negrier S., Cochat P., Bouffet E., Zhou D.C., Franks C.R., Bijman T., Brunat-Mentigny M., Philip T., Kaneko M., Kemshead J., Lampert F., Lee R.E.J., Loo A.T., Pearson A.D.J., Philip T., Roald B., Sawada T., Seeger R.C., Tsuchida Y., Voute P.A. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marrow Transplant. 4:1989;499-503.
10. Fell H.P., Gayle M.A., Grosmaire L., Ledbetter J.A. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL-2. J. Immunol. 146:1991;2446-2452.
11. Frost J.D., Hank J.A., Reaman G.H., Frierdich S.R.N., Seeger R.C., Gan J., Anderson P.M., Ettinger L.J., Cairo M.S., Blazar B.R., Krailo M.D., Matthay K.K., Reisfeld R.A., Sondel P.M. Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus Il-2 in children with refractory neuroblastoma. a report of the children's cancer group Cancer. 80:1997;317-333.
12. Gillies S.D., Young D., Lo K.M., Foley S.F., Reisfeld R.A. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma. 10:1991;347-356.
13. Gillies S.D., Reilly E.B., Lo K.M., Reisfeld R.A. Antibody-targeted interleukin-2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA. 89:1992;1428-1432.
14. Greene L.A., Shain W., Chalazonitis A., Breakfield X., Minna J., Coon H.G., Nirenberg M. Neuronal properties of hybrid neuroblastoma X sympathetic ganglion cells. Proc. Natl. Acad. Sci. USA. 72:1975;4923-4927.
15. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1982;1823-1841.
16. Grimm E.A., Ramsey K.M., Mazumder A., Wilson D.J., Djeu J.Y., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J. Exp. Med. 157:1983;884-897.
17. Gumperz J.E., Parham P. The enigma of the natural killer cell. Nature. 378:1995;245-248.
18. Handgretinger R., Baader P., Dopfer R., Klingebiel T., Reuland P., Treuner J., Reisfeld R.A., Niethammer D. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol. Immunother. 35:1992;199-204.
19. Handgretinger R., Anderson K., Lang P., Dopfer R., Klingebiel T., Schrappe M., Reuland P., Gillies S.D., Reisfeld R.A., Neithammer D. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer. 31:1995;261-267.
20. Hank J.A., Robinson R.R., Surfus J., Mueller B.M., Reisfeld R.A., Cheung N.K., Sondel P.M. Augmentation of antibody-dependent cell-mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res. 50:1990;5234-5239.
21. Honsik C.J., Jung G., Reisfeld R.A. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc. Natl. Acad. Sci. USA. 83:1986;7893-7897.
22. Hornick J.L., Khawli L.A., Hu P., Lynch M., Anderson P.M., Epstein A.L. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood. 89:1997;4437-4447.
23. Huang A.Y., Gulden P.H., Woods A.S., Thomas M.C., Tong C.D., Wang W., Engelhard V.H., Pasternack G., Cotter R., Hunt D., Pardoll D.M., Jaffee E.M. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA. 93:1996;9730-9735.
24. Irie R.F., Morton D.L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. USA. 83:1986;8694-8698.
25. Lode H.N., Xiang R., Varki N.M., Dolman C.S., Gillies S.D., Reisfeld R.A. Targeted interleukin-2 therapy of spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89:1997;1586-1594.
26. Lode H.N., Xiang R., Dreier T., Varki N.M., Gillies S.D., Reisfeld R.A. Natural killer-cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood. 91:1998;1706-1715.
27. Maas R.A., Dullens H.F., Den Otter W. Interleukin-2 in cancer treatment. disappointing or (still) promising? A review Cancer Immunol. Immunother. 36:1993;141-148.
28. Maass G., Schmidt W., Berger M., Schilcher F., Koszik F., Schneeberger A., Stingl G., Birnstiel M.L., Schweighoffer T. Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin-2-secreting tumor cells. three consecutive stages may be required for successful tumor vaccination Proc. Natl. Acad. Sci. USA. 92:1995;5540-5544.
29. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 84:1994;2457-2466.
30. Massague J. The TGF-beta family of growth and differentiation factors. Cell. 49:1987;437-438.
31. Murray J.L., Cunningham J.E., Brewer H., Mujoo K., Zukiwski A.A., Podoloff D.A., Kasi L.P., Bhadkamkar V., Fritsche H.A., Benjamin R.S., Legha S.S., Ater J.L., Jaffe N., Itoh K., Ross M.I., Bucana C.D., Thompson L., Cheung L., Rosenblum M.G. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol. 12:1994;184-193.
32. Niethammer D., Handgretinger R. Clinical strategies for the treatment of neuroblastoma. Eur. J. Cancer. 31:1995;568-571.
33. Pancook J.D., Becker J.C., Gillies S.D., Reisfeld R.A. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol. Immunother. 42:1996;88-92.
34. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:1995;399-415.
35. Parkman R. Is chronic graft versus host disease an autoimmune disease? Curr. Opin. Immunol. 5:1993;800-803.
36. Raulet D.H. Recognition events that inhibit and activate natural killer cells. Curr. Opin. Immunol. 8:1996;372-377.
37. Raulet D.H., Held W. Natural killer cell receptors. the offs and ons of NK-cell recognition Cell. 82:1995;697-700.
38. Reisfeld R.A., Gillies S.D. Recombinant antibody fusion proteins for cancer immunotherapy. Guenthert U., Schlag P., Birchmeier W. Current Topics in Microbiology and Immunology. Attempts to Understand Metastasis Formation III:1996;27-53 Springer-Verlag, Berlin.
39. Reisfeld R.A., Becker J.C., Gillies S.D. Immunocytokines. a new approach to immunotherapy of melanoma Melanoma Res. 7:1997;99-106.
40. Riethmueller G., Schneider-Gaedicke E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Pichlmaier H., Hirche H., Pichelmayr R., Buggisch P., Witte J. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma (The German Cancer Aid 17-1A Study Group). Lancet. 94:1994;1177-1183.
41. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A., Simpson C., Carter C., Bock S., Schwartzentruber D., Wei J.P., White D.E. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319:1988;1676-1680.
42. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210:1989;474-485.
43. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1994;1159-1166.
44. Roszman T., Elliott L., Brooks W. Modulation of T-cell function by gliomas. Immunol. Today. 12:1991;370-374.
45. Roth J.A., Cristiano R.J. Gene therapy for cancer. what have we done and where are we going J. Natl. Cancer Inst. 89:1997;21-39.
46. Ruffini P.A., Rivoltini L., Silvani A., Boiardi A., Parmiani G. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol. Immunother. 36:1993;409-416.
47. Sabzevari H., Gillies S.D., Mueller B.M., Pancook J.D., Reisfeld R.A. A recombinant antibody-interleukin-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA. 91:1994;9626-9630.
48. Saleh M.N., Khazaeli M.B., Wheeler R.H., Dropcho E., Liu T., Urist M., Miller D.M., Lawson S., Dixon P., Russell C.H., LoBuglio A.F. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res. 52:1992;4342-4347.
49. Schwartz R.H. Models of T-cell anergy. is there a common molecular mechanism? J. Exp. Med. 184:1996;1-8.
50. Schwinghammer T.L., Bloom E.J. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin. Pharmacol. 12:1993;736-761.
51. Shiloni E., Eisenthal A., Sachs D., Rosenberg S.A. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J. Immunol. 138:1987;1992-1998.
52. Silverstein, A. M. (1988) A History of Immunology. Jovanovich, H. B. (ed.) Academic Press, San Diego, California.
53. Smith K.A. Lowest dose interleukin-2 immunotherapy. Blood. 81:1993;1414-1423.
54. Sprent J. Antigen-presenting cells. Professionals and amateurs. Curr. Biol. 5:1995;1095-1097.
55. Steimle S. Experts call for action to prevent colon cancer deaths by spurring screening awareness. J. Natl. Cancer Inst. 89:1997;415-416.
56. Tao M.H., Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature. 362:1993;755-758.
57. Tigges M.A., Casey L.S., Koshland M.E. Mechanism of interleukin-2 signaling. mediation of different outcomes by a single receptor and transduction pathway Science. 243:1989;781-786.
58. Uttenreuther-Fischer M.M., Huang C.S., Reisfeld R.A., Yu A.L. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol. Immunother. 41:1995;29-36.
59. Wang X., Desai S., Noronha E., Mittelman A., Ferrone S. The anti-idiotypic approach to active specific immunotherapy of malignant melanoma. Shoenfeld Y., Kennedy R.C., Ferrone S. Idiotypes in Medicine. Autoimmunity, Infection and Cancer:1997;523-536 Elsevier Science B.V, New York.
60. Winkelhake J.L., Gauny S.S. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol. Rev. 42:1990;1-28.
61. Xiang R., Lode H.N., Dolman C.S., Dreier T., Varki N.M., Qian X., Lo K., Lan Y., Super M., Gillies S.D., Reisfeld R.A. Elimination of established murine colon carcinoma metastases by antibody-interleukin-2 fusion protein therapy. Cancer Res. 57:1997;4948-4955.
62. Zheng L.M., Ojcius D.M., Garaud F., Roth C., Maxwell E., Li Z., Rong H., Chen J., Wang X.Y., Catino J.J., King I. Interleukin-10 inhibits tumor metastasis through an NK-cell-dependent mechanism. J. Exp. Med. 184:1996;579-584.